Table III.

Effect of puerarin combined with 5-FU or alone on hepatic and renal function.

Group	n	ALT, U/l (mean±SD)	AST, U/l) (mean±SD)	Urea, μmol/l) (mean±SD)	Cr, μmol/l) (mean±SD)
Puerarin	6	46.17±6.55	143.33±28.93	7.98±2.15	16.64±5.61
5-FU	6	46.00±3.16	144.83±21.27	7.96±0.96	15.86±5.29
Puerarin + 5-FU	6	45.33±8.16	146.67±25.84	8.29±1.59	16.24±3.54
Tumor control	6	46.33±4.08	145.33±14.85	8.05±0.51	16.57±4.54
Normal control	6	46.17±4.92	145.00±6.78	7.91±1.03	16.85±5.74

The groups were treated with puerarin (50 mg/kg/day), 5-FU (12 mg/kg/day), puerarin (50 mg/kg/day) and 5-FU (12 mg/kg/day), tumor control (an equal volume of saline) or normal control (no treatment). No differences in serum ALT, AST, urea or Cr were identified among the groups (P>0.05). 5-Fu, 5-fluorouracil; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine.